Literature DB >> 10754531

A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.

R L Sokoloff1, K C Norton, C L Gasior, K M Marker, L S Grauer.   

Abstract

BACKGROUND: Prostate-specific membrane antigen (PSMA) is a 750-residue integral membrane glycoprotein and the target of an in-vivo imaging agent for metastatic prostate carcinoma (PCa). PSMA expression in normal and diseased prostatic tissues has previously been demonstrated by immunohistochemical techniques. In order to quantify PSMA levels in tissue homogenates and physiological fluids, we have developed a dual monoclonal antibody (mAb) sandwich assay which detects the antigen at a sensitivity <1 ng/mL and which is linear across the working range 0-50 ng/mL.
METHODS: The assay involves capture of the PSMA by a biotinylated mAb (7E11) immobilized onto a streptavidin-coated microtiter plate; this mAb binds to the N-terminus of the antigen. The captured PSMA is detected by an Eu-labelled mAb (PEQ226) which binds in the region corresponding to Residues 134-437 of the antigen. PSMA was purified from LNCaP cells by immunoaffinity chromatography, and used as a calibrator, based on its concentration by the bicinchoninic acid (BCA) protein assay.
RESULTS: The assay was applied to a panel of normal and tumor tissues. Levels were highest in the prostate tissues (292-4254 ng/mg protein). Low levels (21-51 ng/mL) were observed in membranes from ovary and breast, and neglible levels (1-10 ng/mg) in membranes from skin, liver, intestine, and kidney. Levels in the corresponding cytosol fractions were 20-to 50-fold lower. The average PSMA level in seminal fluid from 21 donors was 9, 012 ng/mL. On average, levels in normal-male urine (3.47 ng/mL) were ten-fold higher than in normal-female urine (0.3 ng/mL).
CONCLUSIONS: This report is the first to describe absolute quantitation of PSMA in tissues and fluids. Congruent with earlier tissue studies based on immunohistochemical staining and Western-blot analysis, prostate tissue membranes expressed the highest levels of PSMA. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754531     DOI: 10.1002/(sici)1097-0045(20000501)43:2<150::aid-pros10>3.0.co;2-b

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  46 in total

1.  Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Authors:  Steven M Santana; He Liu; Neil H Bander; Jason P Gleghorn; Brian J Kirby
Journal:  Biomed Microdevices       Date:  2012-04       Impact factor: 2.838

Review 2.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

3.  Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.

Authors:  C A S Regino; K J Wong; D E Milenic; E H Holmes; K Garmestani; P L Choyke; M W Brechbiel
Journal:  Curr Radiopharm       Date:  2009-01

Review 4.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Engineering chemically modified viruses for prostate cancer cell recognition.

Authors:  K Mohan; G A Weiss
Journal:  Mol Biosyst       Date:  2015-12

6.  Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.

Authors:  Anna Plechanovová; Youngjoo Byun; Glenda Alquicer; L'ubica Skultétyová; Petra Mlčochová; Adriana Němcová; Hyung-Joon Kim; Michal Navrátil; Ronnie Mease; Jacek Lubkowski; Martin Pomper; Jan Konvalinka; Lubomír Rulíšek; Cyril Bařinka
Journal:  J Med Chem       Date:  2011-10-11       Impact factor: 7.446

Review 7.  A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.

Authors:  Denise S O'Keefe; Dean J Bacich; Steve S Huang; Warren D W Heston
Journal:  J Nucl Med       Date:  2018-04-19       Impact factor: 10.057

8.  Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer.

Authors:  Waseem Hariri; Thangirala Sudha; Dhruba J Bharali; Huadong Cui; Shaker A Mousa
Journal:  Pharm Res       Date:  2015-03-12       Impact factor: 4.200

9.  Sub-nanomolar detection of prostate-specific membrane antigen in synthetic urine by synergistic, dual-ligand phage.

Authors:  Kritika Mohan; Keith C Donavan; Jessica A Arter; Reginald M Penner; Gregory A Weiss
Journal:  J Am Chem Soc       Date:  2013-05-13       Impact factor: 15.419

10.  Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Authors:  Scott T Tagawa; Matthew I Milowsky; Michael Morris; Shankar Vallabhajosula; Paul Christos; Naveed H Akhtar; Joseph Osborne; Stanley J Goldsmith; Steve Larson; Neeta Pandit Taskar; Howard I Scher; Neil H Bander; David M Nanus
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.